Abstract: The oligonucleotides have sufficient guanosine to form a guanosine tetrad and can be composed of at least about 40% guanosine nucleotides, the nucleotide sequence containing at least two runs of at least two guanosines. Some of the new oligonucleotides also contain phosphorothioate backbones and 3′ end modifications. Representative guanosine-rich oligonucleotides of the present invention demonstrate anti-viral activity in tissue culture against HSV-2, HIV-1, HCMV and FMLV, and show specific inhibition of bacterial RNA polymerase enzymes T7 and T3, the FMLV and HIV-1 reverse transcriptase enzyme and eukaryotic RNA polymerase.
Type:
Grant
Filed:
October 23, 1995
Date of Patent:
February 6, 2001
Assignee:
Aronex Pharmaceuticals, Inc.
Inventors:
Robert F. Rando, Susan Fennewald, Joseph G. Zendegui, Joshua O. Oiwana, Michael E. Hogan